Csl Limited

Zenyth Operations Pty. Ltd.

Medimmune Limited

Merck + Co., Inc.

The Walter and Eliza Hall Institute of Medical Research

Louis Jerry Fabri

Andrew Donald Nash

Manuel Baca

Zhiqiang An

William Strohl

Dennis M Zaller

Douglas James Hilton

Nicos Anthony Nicola

Ralph Raymond Minter

Matthew Alexander Sleeman

Emma Suzanne Cohen

Felicity Meredith Dunlop

Paula Rosamund Harrison

Tetsuo Kojima

Tracy Ann Willson

Perry Francis Bartlett

Sandra Elaine Nicholson

Warren S Alexander

Yasufumi Kikuchi

Pierre David Scotney

Jian Guo Zhang

Jian-Guo Zhang

Alison Farley

Steven Rakar

Masakazu Hasegawa

Yasuhiko Nakata

Kate Reid

Kim Maree Jachno

Masatsugu Maeda

William R Strohl

High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13R&#x3b1;1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13R&#x3b1;1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13R&#x3b1;1-mediated activities are also disclosed.

High affinity antibody antagonists of interleukin-13 receptor alpha 1

Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFR&#x3b1;), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis.

Antibody molecule for human GM-CSF receptor alpha

The present invention relates generally to the field of cancer therapy and prophylaxis. More particularly, the present invention provides growth factor antagonists which inhibit the growth of cancers including tumors and pre-cancerous tissue. Even more particularly, the present invention is directed to antagonists of vascular endothelial growth factor-B and their use to inhibit the growth of cancer including tumor tissue and pre-cancerous tissue.

Method of treating cancer comprising a VEGF-B antagonist

Antibody antagonists of human interleukin-13 receptor alpha 1 which bind to hIL-13R&#x3b1;1 through domain 3 of the extracellular region of the receptor and inhibit IL-13 receptor-mediated signaling by IL-13 are disclosed herein. These antibodies have uses inter alia in the treatment or prevention of IL-13-related disorders and diseases. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing hIL-13R&#x3b1;1-mediated activities are also disclosed.

Anti-IL-13R&#x3b1;1 antibodies and their uses thereof

Binding members are provided for alpha chain of receptor for granulocyte macrophage colony stimulating factor (GM-CSFR&#x3b1;), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g. rheumatoid arthritis, asthma, allergic response, multiple sclerosis, myeloid leukaemia and atherosclerosis is also provided.

The present invention relates generally to antibodies that bind to the Interleukin-13 receptor.alpha.1 chain (IL-13R.alpha.1) and antagonize IL-13 receptor-mediated signaling by IL-13 and/or IL-4. More particularly, the present invention provides humanized or human antibodies to mammalian and in particular IL-13R.alpha.1. These antibodies have uses in the treatment or prevention of IL-13- and/or IL-4-mediated diseases or conditions. The present invention further contemplates a method of modulating IL-13- and/or IL-4-mediated diseases or conditions by the administration of the subject antibodies. The present invention further provides an assay system useful for identifying antibodies or other agents which modulate IL-13 and/or IL-4 signaling through an IL-13 receptor complex. Accordingly, a method of screening for modulators of IL-13R.alpha.1/ligand interaction is also provided.

Monoclonal antibody against interleukin-13 receptor alpha 1 (IL-13Ralpha1)

Antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are useful in the inhibition of IL-13R&#x3b1;1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13R&#x3b1; activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13R&#x3b1;1-mediated activities are also disclosed.

Antibody antagonists of interleukin-13 receptor &#x3b1;1

The present invention relates generally to antibodies that bind to the Interleukin-13 receptor &#x3b1;1 chain (IL-13R&#x3b1;1) and antagonize IL-13 receptor-mediated signaling by IL-13 and/or IL-4. More particularly, the present invention provides humanized or human antibodies to mammalian and in particular IL-13R&#x3b1;1. These antibodies have uses in the treatment or prevention of IL-13- and/or IL-4-mediated diseases or conditions. The present invention further contemplates a method of modulating IL-13- and/or IL-4-mediated diseases or conditions by the administration of the subject antibodies. The present invention further provides an assay system useful for identifying antibodies or other agents which modulate IL-13 and/or IL-4 signaling through an IL-13 receptor complex. Accordingly, a method of screening for modulators of IL-13R&#x3b1;1/ligand interaction is also provided.

Monoclonal antibody against interleukin-13 receptor alpha 1 (IL-13Ra1)

The present invention relates generally to a method for regulating cytokine signaling and agents useful for same. The method of the present invention is predicated in part on the identification of the molecular target of suppressor of cytokine signaling (SOCS) interaction in controlling cytokine signaling. The identification of the molecular target permits the development of assays to screen for a range of agonists and antagonists useful in modulating cytokine function. The present invention further provides, therefore, screening assays and more particularly high through-put screening assays for agonists and antagonists of SOCS-receptor interaction. Such agonists and antagonists are useful in the manufacture of medicaments for controlling cytokine signaling. Control of cytokine signaling is important for the treatment of a range of conditions including cancer, inflammatory conditions, immunological disorders and any other conditions involving aberrations of signal transduction.

Methods of regulating cytokine signalling

The present invention relates generally to a novel haemopoietin receptor or derivatives thereof and to genetic sequences encoding same. Interaction between the novel receptor of the present invention and a cytokine ligand facilitates proliferation, differentiation and survival of a wide variety of cells. The novel receptor and its derivatives and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.

Haemopoietin receptor and genetic sequence encoding same

Growing community of inventors

Diamond Creek, Australia

Louis Jerry Fabri